ARWR Stock Overview
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Arrowhead Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$28.60 |
52 Week High | US$42.48 |
52 Week Low | US$20.67 |
Beta | 0.72 |
1 Month Change | -8.23% |
3 Month Change | -6.54% |
1 Year Change | 17.07% |
3 Year Change | -57.36% |
5 Year Change | 47.80% |
Change since IPO | -45.00% |
Recent News & Updates
Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package
Mar 08Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Feb 19Recent updates
Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package
Mar 08Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Feb 19Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy
Jan 21Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now
Dec 25Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?
Sep 19Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up
Apr 17Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now
Mar 10A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jan 24We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn
Oct 24Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities
Sep 12Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming
Aug 23Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease
Aug 17Arrowhead Pharmaceuticals: An RNAi Name To Know
Jul 28Arrowhead Pharmaceuticals names internal officer as new COO
Jul 20Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs
Jul 05Arrowhead Pharma: We Can Afford To Wait For More Proof
Jun 28Companies Like Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Afford To Invest In Growth
Jun 18Arrowhead Pharma: Know Pros' Calcs For Coming Stock Prices
Apr 14Are Investors Undervaluing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) By 46%?
Feb 08Arrowhead: 2021 Was A Struggle Valuation Wise - Things May Get Worse In 2022
Jan 26Accumulate Arrowhead For Its RNAi Pipeline
Jan 17Johnson & Johnson's JNJ-3989 News Could Propel Arrowhead Stock To New All-Time Highs
Nov 03Are Investors Undervaluing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) By 34%?
Oct 09The Partnership Effect: Arrowhead Forges Its Future
Aug 27Shareholder Returns
ARWR | US Biotechs | US Market | |
---|---|---|---|
7D | 1.3% | 0.9% | 0.4% |
1Y | 17.1% | 10.3% | 28.8% |
Return vs Industry: ARWR exceeded the US Biotechs industry which returned 10.3% over the past year.
Return vs Market: ARWR underperformed the US Market which returned 28.8% over the past year.
Price Volatility
ARWR volatility | |
---|---|
ARWR Average Weekly Movement | 9.6% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ARWR's share price has been volatile over the past 3 months.
Volatility Over Time: ARWR's weekly volatility (10%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1989 | 525 | Chris Anzalone | https://arrowheadpharma.com |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases.
Arrowhead Pharmaceuticals, Inc. Fundamentals Summary
ARWR fundamental statistics | |
---|---|
Market cap | US$3.56b |
Earnings (TTM) | -US$296.81m |
Revenue (TTM) | US$181.74m |
19.5x
P/S Ratio-11.9x
P/E RatioIs ARWR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ARWR income statement (TTM) | |
---|---|
Revenue | US$181.74m |
Cost of Revenue | US$0 |
Gross Profit | US$181.74m |
Other Expenses | US$478.55m |
Earnings | -US$296.81m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.40 |
Gross Margin | 100.00% |
Net Profit Margin | -163.32% |
Debt/Equity Ratio | 157.6% |
How did ARWR perform over the long term?
See historical performance and comparison